FDAnews
www.fdanews.com/articles/102669-allos-to-continue-propel-trial

Allos to Continue PROPEL Trial

December 31, 2007

An independent data monitoring committee has completed a safety review of Allos Therapeutics’ Phase II trial of PDX in 65 patients with relapsed or refractory peripheral T-cell lymphoma.

The committee recommended the continuation of the PROPEL trial of PDX (pralatrexate) per protocol.

The interim assessment was based upon an evaluation of patients who had completed at least one cycle of treatment with PDX.

Allos said it expects to complete patient enrollment in the PROPEL study in the second quarter of the year.